Why the study?
Does endothelin-1 inhibit ex vivo platelet aggregation in anesthetized rabbits?
Does endothelin-1 inhibit ex vivo platelet aggregation in anesthetized rabbits?
Endothelin-1 inhibits platelet function in vivo by stimulating the release of antiplatelet cyclo-oxygenase products such as prostacyclin.
Answers are grounded in this paper and cite their sources.
ET-1 inhibits rabbit platelet aggregation via COX products; hypothesis-generating for human thrombosis, no practice change.
The effects of porcine endothelin (endothelin-1, ET-1; 1 nmol/kg i.a.) on ex vivo platelet aggregation and platelet cAMP/cGMP levels were investigated in the anesthetized rabbit. ET-1 inhibited ADP-induced platelet aggregation by 83 +/- 9% within 5 min (p less than 0.01). This ET-1-induced inhibition of platelet aggregation lasted for 30 min and was associated with a significant (five- to sixfold) increase in platelet cAMP. However, platelet cGMP levels were unaffected. Indomethacin (5 mg/kg i.v., 20 min prior to ET-1) abolished the ET-1-induced inhibition of ex vivo platelet aggregation as well as the corresponding augmentation of platelet cAMP. Thus, ET-1 inhibits platelet function in vivo due to the release into the circulation of antiplatelet cyclo-oxygenase products, such as prostacyclin (or PGD2).
No takes yet. Share an insight, caveat, or question.
Thiemermann et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: